Policy Briefings

SWHR regularly holds briefings on a variety of women’s health and research-related subjects. These briefings are attended by Congressional staff, federal agency personnel, advocacy group representatives and others to educate attendees about issues important to women’s health.

U.S. Presidential Election Letters

SWHR sent a letter congratulating the 2016 presidential election winner.

SWHR sent letters congratulating the 2016 presidential election nominees and urging them to make women’s health a priority in their platforms.

Congressional Testimony

As the thought leader in advocating for research on sex differences, SWHR is often called upon by Congressional Committees to offer expert testimony on a variety of subject areas. An archive of our past Congressional Testimony is below.

Written Testimony for Federal Funding

Policy Letters

As part of its advocacy mission, the Society for Women’s Health Research monitors the activities of the executive branch in the areas of women’s health and research. At the request of various federal agencies, SWHR periodically submits public comment letters detailing its positions on issues pertaining to SWHR’s public policy priorities.

  • SWHR provided its input on the National Institutes of Health (NIH) strategic plan for research on women’s health. NIH Office of Research on Women’s Health Director Dr. Janine Clayton called the plan’s development “one of the most exciting activities taking place this year.” Read SWHR’s suggestions on topics under consideration to stimulate new research areas, priorities, and approaches to help put science to work for the health of women. (November 10, 2017)
  • SWHR issued a letter to the Office of Human Research Protections (OHRP) on their Federal Policy for the Protection of Human Subjects, or Common Rule (December 4, 2015)
  • SWHR issued a letter to the National Institute on Drug Abuse (NIDA) on their draft strategic plan (October 30, 2015)
  • SWHR joined other advocacy groups in asking Chairman Upton and Ranking Member Pallone of the House Committee on Energy and Commerce that Risk Evaluation and Mitigation Strategies (REMS) be used in generic medicines to ensure rigorous safeguards. (April 8, 2015)
  • SWHR issued a letter to the Director of the National Institute of Drug Abuse (NIDA) in support of the NIDA Strategic Plan’s consideration of the impact of sex and gender on drug abuse and addiction. (January 30, 2015)

Past Policy Letters

Commentary Letters